tegafur has been researched along with Glioblastoma in 3 studies
Glioblastoma: A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Controlled, prospective, randomized studies were performed to evaluate the effects of 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3- (2-chloroethyl)-3-nitrosourea hydrochloride (ACNU) and ACNU plus tegafur as additions to radiotherapy for the treatment of malignant gliomas." | 9.05 | [Evaluation of ACNU alone and combined with tegafur as additions to radiotherapy of the treatment of malignant gliomas--a cooperative clinical trial]. ( Abe, H; Kitamura, K; Matsutani, M; Miwa, T; Nomura, K; Suzuki, J; Takakura, K; Takeuchi, K; Tanaka, R; Ushio, Y, 1985) |
| "Controlled, prospective, randomized studies were performed to evaluate the effects of 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3- (2-chloroethyl)-3-nitrosourea hydrochloride (ACNU) and ACNU plus tegafur as additions to radiotherapy for the treatment of malignant gliomas." | 5.05 | [Evaluation of ACNU alone and combined with tegafur as additions to radiotherapy of the treatment of malignant gliomas--a cooperative clinical trial]. ( Abe, H; Kitamura, K; Matsutani, M; Miwa, T; Nomura, K; Suzuki, J; Takakura, K; Takeuchi, K; Tanaka, R; Ushio, Y, 1985) |
| "Nineteen patients with brain tumors were orally administered 300 mg of UFT (a combination of FT and uracil with a molar ratio being 1:4) before operation and the concentrations of FT, 5-FU and Uracil in tumors and serum were measured by chemical assay." | 1.27 | [5-FU concentration in brain tumors after co-administration of FT and uracil]. ( Matsumoto, S; Nogaki, H; Tamaki, N; Taomoto, K, 1983) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nogaki, H | 1 |
| Taomoto, K | 1 |
| Tamaki, N | 1 |
| Matsumoto, S | 1 |
| Sueyoshi, K | 1 |
| Majima, H | 1 |
| Ushio, Y | 1 |
| Abe, H | 1 |
| Suzuki, J | 1 |
| Tanaka, R | 1 |
| Kitamura, K | 1 |
| Miwa, T | 1 |
| Matsutani, M | 1 |
| Takeuchi, K | 1 |
| Takakura, K | 1 |
| Nomura, K | 1 |
1 trial available for tegafur and Glioblastoma
| Article | Year |
|---|---|
[Evaluation of ACNU alone and combined with tegafur as additions to radiotherapy of the treatment of malignant gliomas--a cooperative clinical trial].
Topics: Adolescent; Adult; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Child; Child, Preschool; Cli | 1985 |
2 other studies available for tegafur and Glioblastoma
| Article | Year |
|---|---|
[5-FU concentration in brain tumors after co-administration of FT and uracil].
Topics: Brain Neoplasms; Drug Therapy, Combination; Fluorouracil; Glioblastoma; Humans; Meningeal Neoplasms; | 1983 |
[Cerebrospinal fluid distributions of systemically administered fluorinated pyrimidines].
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Ependymoma; Female; Fluorouracil; Glioblastoma; | 1983 |